Title:

Effectiveness of COVID-19 Vaccines and Post-vaccination SARS-COV 2 Infection, Hospitalization, and Mortality: a Systematic Review and Meta-analysis of Observational Studies.

Kazem Rahmani¹, Rasoul Shavaleh^{1*}, Mahtab Forouhi², Hamideh Feiz Disfani³, Mostafa Kamandi⁴, Aram Asareh Zadegan Dezfuli⁵, Rozita Khatamian Oskooi⁶, Molood Foogerd⁷, Moslem Soltani⁸.

1-Department of Epidemiology and Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.

2- Department of Pharmacy, Shahid Behest University of medical sciences, Tehran, Iran.

3- Department of Emergency Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4- Hematologist-Oncologist, Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

5- Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

6- Department of Emergency Medicine, Faculty of Medicine, Birgand University Of Medical Sciences, Birgand, Iran.

7- Department of Emergency Medicine, Faculty of Medicine, Birgand University Of Medical Sciences, Birgand, Iran.

8- Department of Gastroenterology and Hepatology, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.

Corresponding Authors:

Rasoul Shavaleh: Department of Epidemiology and Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.

E-mail: rasoul.shavaleh@gmail.com

Phone Number: +989149783098

Abstract:

Introduction & Objective: Vaccination is one of the most important and effective ways of preventing infectious diseases, and has recently been used in the COVID-19 epidemic and pandemic. The present meta-analysis study aimed to evaluate the effectiveness of COVID-19 vaccines in reducing the incidence of infection, hospitalization, and mortality in observational studies.

Materials and Methods: A systematic search was performed independently in Scopus, PubMed, ProQuest, and Google Scholar electronic databases as well as Preprint servers using the keywords under study. The heterogeneity of the studies was assessed using I^2 and χ^2 statistics, according to which the I^2 of $> 50\%$ and P-value < 0.1 was reported as heterogeneity of the studies. In addition, the Pooled Vaccine Effectiveness (PVE) obtained from the studies was calculated by converting $(1 - \text{Pooled estimate} \times 100\%)$ based on the type of outcome.

Results: A total of 54 records were included in this meta-analysis. The rate of PVE against SARS-COV 2 infection was about 71% (OR = 0.29, 95% CI: 0.23-0.36) in the first dose and 87% (OR = 0.13, 95% CI: 0.08-0.21) in the second, and the highest effectiveness in the first and second doses was that of BNT162b2 mRNA and combined studies. The PVE versus COVID-19-associated hospitalization was 73% (OR = 0.27, 95% CI: 0.18-0.41) in the first dose and 89% (OR = 0.11, 95% CI: 0.07-0.17) in the second. mRNA-1273 and combined studies in the first dose and ChAdOx1 and mRNA-1273 in the second dose had the highest effectiveness. Regarding the COVID-19-related mortality, PVE was about 28% (HR = 0.39, 95% CI: 0.23-0.45) in the first dose and 89% (HR = 0.11, 95% CI: 0.03-0.43) in the second.

Conclusion: The evidence obtained from this study showed that the effectiveness of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 in the first and second doses, and even combined studies were associated with increased effectiveness against SARS-COV2 infection, hospitalization, and death from COVID-19. In addition, considering that the second dose was significantly more efficient than the first one, a booster dose injection could be effective in high-risk individuals. On the other hand, it was important to observe other prevention considerations in the first days after taking the first dose.

Keywords: SARS-COV2 infection, hospitalization, mortality, COVID-19, effectiveness

Introduction:

Over the past years, emerging and re-emerging diseases were a public health challenge in human populations with high mortality rates (1). In December 2019, a new outbreak of coronavirus by SARS coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China, and on March 11, 2020, the World Health Organization and the CDC (Center for Disease Control and Prevention) introduced it as COVID-19 (2-4). The disease has been diagnosed with more than 195 million cases worldwide and more than 4 million deaths. As a result of this pandemic, restrictions and programs to prevent and control the infection were implemented by governments around the world (5, 6). The rapid spread of infection among individuals, the lack of symptoms or mild ones during the incubation period, and even the contagious nature of the disease during incubation have made the epidemic extremely difficult to control. Hence, most prevention programs were concentrated on making vaccine against SARS -CoV-2, and in several countries, some vaccines were licensed for emergency use (7-9). Clinical trials of manufactured vaccines showed that the effectiveness of Oxford-AstraZeneca (ChAdOx1), Pfizer BioNTech (BNT162b2 mRNA), Moderna (mRNA-1273), and Johnson & Johnson (Ad26.COV2.S) vaccines was 70.4%, 95%, 94.1%, and 66.9%, respectively (10-13). On the other hand, it should be noted that clinical trials are designed under controlled conditions for the voluntary entry of certain individuals and groups and the availability of the data of censored individuals (14), which can differ from the general population (15, 16). Furthermore, several observational studies were designed and conducted to determine the effectiveness of COVID-19 vaccines in various populations and groups under mass vaccination in order to not only indicate the effectiveness of COVID-19 vaccines, but also to compare the incidence of infection, mortality, and hospitalization due to COVID-19 in larger sample sizes and with more follow-ups (17-19). In the meantime, considering the wide range of evidence obtained from the effectiveness of vaccination in different groups, it seemed necessary to summarize them through meta-analysis studies to be presented to policy makers. Thus, the aim of this study was to evaluate the effectiveness of COVID-19 vaccines, the incidence of SARS-COV-2 infection, and the hospitalization and COVID-19-related mortality rates after vaccination in observational studies.

Materials and methods

Search Strategy

A systematic search of PubMed, Scopus, ProQuest, and Google Scholar databases as well as the Preprint servers including medRxiv and Research Square was done to identify the studies related to the keywords studied based on the Medical Subject Headings (MeSH) published until October 15, 2021, with full texts in English, without any spacial restrictions. The search was done blindly and independently by two researchers (K Rahmani & R Shavale) using the following keywords in the abovementioned databases: COVID-19; SARS-COV-2; coronavirus; vaccine; post-vaccination; mortality; hospitalization; readmission; reinfection; morbidity; and Breakthrough infections. The non-common cases that differed in the searches of the two researchers were dealt with by other researchers. Duplicates were also identified by title, author's name, and journal name.

Eligibility Criteria

All of the observational and longitudinal studies published in English that had assessed the effectiveness, incidence of SARS-COV 2 infection, hospitalization rates, and mortality rates after COVID-19 vaccination were included without any special restrictions. The studies that had examined the confirmed cases of SARS-COV 2 infection from positive real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR or PCR) tests were also included, and the antibody-based studies and the ones based on other diagnostic methods were excluded from the review process. In addition, Case report, Case series, Letter or Correspondence, Animal studies, and studies with Mathematical model analysis were also excluded (flowchart 1). The studies on autoimmune, immunosuppressed, dialysis patients, or the patients with kidney problems and mental disorders in whom the severity of the disease varied were excluded as well. The studies that lacked an unvaccinated group to compare the results were not included in the review process. The studies on inactive vaccines such as CoronaVac and Covaxin as well as Ad26.COV2.S were excluded from the analysis due to their low frequencies.

Outcomes

The outcomes were as follows:

- 1- Effectiveness of the vaccines against infection in the subjects studied, which was a relative reduction of RT-PCR test confirmed by throat swab, nasal swab, oropharyngeal swab, or saliva and sputum for Covid-19 in the vaccinated groups compared to the unvaccinated ones.
- 2- Effectiveness of the vaccines against hospitalization of the subjects in the studies was a relative reduction of hospitalization of the individuals whose RT-PCR test 14 days before and after hospitalization was confirmed through throat swab, nasal samples, oropharyngeal swab, or saliva and sputum for Covid-19 disease in the vaccinated groups compared with the unvaccinated ones.
- 3- Effectiveness of the vaccines against the hospitalization of the subjects in the studies was a relative reduction in deaths within 40 days after the RT-PCR test confirmed by throat swab,

nasal swab, oropharyngeal swab, and or saliva and sputum for Covid-19 disease in the vaccinated groups compared with the unvaccinated ones (20).

Data extraction

The data of the studies presented in flowchart 1 were extracted separately by two researchers. The extracted information included the names of the corresponding authors, types of vaccines studied, places of study, types of study, description of study conditions including study groups, positive SARS-COV 2 test cases in vaccinated and unvaccinated groups by the first and second doses, cases of death and hospitalization associated with COVID-19 in vaccinated and unvaccinated groups by the first and second doses, and infection and death HRs due to COVID-19 with 95% confidence interval between the first and second doses.

The HR of the studies was considered as the risk ratio of the vaccinated to non-vaccinated individuals, and in the studies whose HR was calculated as the risk ratio of unvaccinated to vaccinated people, it was converted with $\frac{1}{HR}$ and 95% confidence intervals. Also, in the studies that had mentioned the effectiveness percentage through $1 - HR \times 100\%$, the HR and 95% of confidence intervals were converted by calculating $1 - (\frac{HR}{100\%})$. On the other hand, the follow-up periods in the studies were considered based on Pearson-Day, even in the studies where the follow-up periods were Pearson-Week and Pearson-Year.

Considering the studies examined, the people who had not taken any vaccines were classified as unvaccinated, and those who were on the $\geq 7^{\text{th}}$ day after the first dose and $\geq 5^{\text{th}}$ day after the second dose were classified as partial vaccinated and fully vaccinated, respectively.

Statistical Analysis

A meta-analysis was carried out using the Random-effects Model and the Mantel-Haenszel weighting method for each study to estimate Pooled Odds Ratio, Pooled Hazard Ratio, and Pooled Incidence Ratio, and 95% confidence interval was used for the studies with similar effect measures (OR, IRR or HR). The heterogeneity of the studies was assessed using the I^2 and χ^2 statistics, according to the results of which $I^2 > 50\%$ with P-value < 0.1 showed the heterogeneity of the studies. In addition, to calculate the Pooled Vaccine Effectiveness (PVE) obtained from the studies, the following conversions were used: $1 - \text{Pooled Odds Ratio} \times 100\%$, $1 - \text{Pooled Hazard Ratio} \times 100\%$, and $1 - \text{Pooled Rate Ratio} \times 100\%$. The statistical analysis was performed using R version 4.1.1 and Metafor Package.

Figure 1- PRISMA flow diagram of the studies included in meta-analysis

Results

Based on the research strategy, 54 records on the effectiveness, incidence of SARS-COV 2 infection, mortality, and hospitalization associated with COVID-19 vaccination were finally reviewed (flowchart 1). The studies were analyzed based on the type of indices extracted. BNT162b2 mRNA accounted for the most frequent studies on vaccine types. In terms of location, most of the studies had been conducted in the USA, UK, Spain, and Israel, respectively (Tables 1 to 5). All of the studies had been carried out on the age groups >14 years.

Effectiveness of Vaccines against Covid-19 Infection in Partial Vaccinated Group

The results of 28 studies presented as forest plot using effect measure pooled OR in Figure 1 showed that the effectiveness of the first dose (Partial) of the studied vaccines against COVID-19 infection was 71% in total. This effectiveness varied according to the type of vaccine ($p - value_{subgroup} < 0.05$); i.e. the effectiveness of BNT162b2 mRNA vaccine against COVID-19 infection was 72% (Pooled OR = 0.28, 95% CI: 0.13-0.60), the effectiveness of mRNA-1273 vaccine was 69% (Pooled OR = 0.31, 95% CI: 0.22-0.44), and that of ChAdOx1 vaccine was 51% (Pooled OR = 0.49 95% CI: 0.41-0.59). Furthermore, the combined studies that had examined the vaccines (BNT162b2 mRNA, mRNA-1273, ChAdOx1) reported an approximate effectiveness of 79% (Pooled OR = 0.21, 95% CI: 0.06-0.76) (Figure 1).

Figure 1. Partial vaccinated effectiveness of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines against SARS-COV 2 infection

Effectiveness of Vaccines against Covid-19 Infection in Full Vaccinated Group

The results of 20 studies presented as forest plot using effect measure pooled OR in Figure 2 showed that the total effectiveness of the second dose of the vaccines (Full vaccinated) against COVID-19 infection was 87% (OR = 0.13, 95% CI: 0.08-0.22); i.e. the effectiveness of the second dose of BNT162b2 mRNA vaccine against COVID-19 infection was 88% (OR = 0.12, 95% CI: 0.05-0.27), that of mRNA vaccine -1273 was 80% (OR = 0.20, 95% CI: 0.08-0.52), and the effectiveness of the second dose of ChAdOx1 vaccine was 5184% (OR = 0.16, 95% CI: 0.06 -0.45). In addition, the combined studies that examined the vaccines (BNT162b2 mRNA, mRNA-1273, ChAdOx1) reported an approximate effectiveness of 0.89% for the second doses (OR = 0.13, 95% CI: 0.08-0.22). The results of the sub group analysis in the second dose showed well that there was no difference between different types of vaccines in terms of their effectiveness ($p - value_{subgroup} = 0.81$) (Figure 2).

Figure 2. Full vaccinated effectiveness of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines against SARS-CoV 2 infection.

Effectiveness of vaccines against hospitalization of COVID-19 patients in the Partial vaccinated group

The total effectiveness of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines as well as the Combined studies in the first dose against COVID-19-related hospitalization was 73% (OR = 0.27, 95% CI: 0.17-0.44) (Figure 3). Considering the type of vaccines, the results of Pooled estimate showed that the effectiveness of BNT162b2 mRNA vaccine was about 85% (OR = 0.15, 95% CI: 0.04-0.56), that of mRNA-1273 was 73% (OR = 0.27, 95% CI: 0.21 - 0.34), and the effectiveness of ChAdOx1 vaccine was about 56% (OR = 0.44, 95% CI: 0.29-0.67). In the Combined studies, the efficacy of the vaccines was about 62% (OR = 0.38, 95% CI: 0.23-0.62). The results of the subgroup on the type of vaccines also indicated no difference between the effectiveness of the vaccines in the first dose against hospitalization with COVID-19 (P value = 0.11).

Figure 3- Partial effectiveness of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines against COVID-19-related hospitalization

Effectiveness of vaccines against hospitalization of COVID-19 patients in Full vaccinated group

The total effectiveness of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines as well as the Combined Studies in the second dose against COVID-19-related hospitalization was about 89% (OR = 0.11, 95% CI: 0.08-0.16) while BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines had the effectiveness of 91%, 88%, and 91%, respectively. In addition, the effectiveness of the vaccines in the combined studies was about 86% (OR = 0.14, 95% CI: 0.03-0.60). The results of the sub group analysis in the second dose showed well that there was no difference between the effectiveness rates of different types of vaccines against hospitalization ($p - value_{subgroup} = 0.09$) (Figure 4).

Figure 4- Full effectiveness of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines against COVID-19-related hospitalization

Effectiveness of vaccines against infection using COVID-19-associated IRR in partially vaccinated individuals

The results indicated that the rate of COVID-19-related infection in the people vaccinated with BNT162b2 mRNA, mRNA-1273, ChAdOx1, and Combined studies in the first dose was reduced by about 60% (IRR = 0.4, 95% CI: 0.30-0.53 (Figure 5). The reduction in

COVID-19- related infection rate in the individuals vaccinated with the first dose of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 was about 56% (IRR = 0.44, 95% CI: 0.31-0.61), 66% (IRR = 0.34, 95% CI: 0.11-1.02), and 46% (IRR = 0.54, 95% CI: 0.12-2.48), respectively. In the Combined studies, the reduction in COVID-19-related infection was about 86% (IRR = 0.14, 95% CI: 0.10-0.20) as well. The results of the sub group analysis in the first dose showed well that there was a difference between the effectiveness rates of different types of vaccine against SARS-COV 2 infection ($p - value_{subgroup} < 0.01$) (Figure 5).

Figure 5 - Effectiveness of vaccines against infection using COVID-19-related IRR in partial vaccinated individuals

Effectiveness of vaccines using COVID-19-associated IRR in full-vaccinated individuals

In the people vaccinated with the second dose (Full vaccinated) of BNT162b2 mRNA, mRNA-1273, ChAdOx1, and Combined studies, the rate of COVID-19-related infection had reduced by about 90% (IRR = 0.10, 95% CI: 0.07- 0.17) (Figure 6). The reduction in COVID-19- related infection rate in the individuals vaccinated with the second dose of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 was about 89% (IRR = 0.11, 95% CI: 0.08-0.16), 91% (IRR = 0.09 , 95% CI: 0.04-0.17), and 55% (IRR = 0.45, 95% CI: 0.43-0.47), respectively (Figure 6). In the Combined studies, the COVID-19-related mortality after the second dose had reduced by about 95% (IRR = 0.05, 95% CI: 0.02-0.13). The results of the sub group analysis in the second dose showed well that there was a difference between the effectiveness rates of different types of vaccine against SARS-COV 2 infection ($p - value_{subgroup} < 0.01$) (Figure 6).

Figure 6 - Effectiveness of vaccines using COVID-19-related IRR in full vaccinated individuals

Effectiveness of vaccines against COVID-19 infection using Hazard ratio in partial-vaccinated individuals

Studying the Hazard ratio associated with SARS-COV 2 infection showed that vaccination with the first dose of BNT162b2 mRNA, mRNA-1273, ChAdOx1, and Combined studies reduced the risk of SARS-COV 2 infection by about 69% (HR = 0.31 , 95% CI: 0.20-0.46) (Figure 7). In other words, the first doses of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines had reduced the risk ratio of SARS-COV 2 infection by about 70% (HR = 0.30, 95% CI: 0.19-0.47), 83% (HR = 0.17, 95% CI: 0.03-1.01), and 39% (HR = 0.61, 95% CI: 0.51-0.72), respectively. On the other hand, the combined studies had reduced the risk of SARS-COV 2 infection by about 83% (HR = 0.17, 95% CI: 0.03-1.01). The results of the sub group analysis in the first dose showed well that there was a difference between the effectiveness rates of different types of vaccine against SARS-COV 2 infection ($p - value_{subgroup} < 0.01$) (Figure 7).

Figure 7- Effectiveness of vaccines against COVID-19 infection using Hazard ratio in partial-vaccinated individuals

Effectiveness of vaccines against COVID-19 infection using Hazard ratio in full-vaccinated individuals

In the individuals vaccinated with the second dose (Full vaccinated) of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines as well as the combined studies, the risk of SARS-COV 2 infection had reduced by about 84% (Figure 8). However, the second dose of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines had reduced the Hazard ratio by about 79% (HR = 0.21, 95% CI: 0.14-0.31), 87% (HR = 0.13, 95% CI: 0.11-0.15), and 86% (HR = 0.14, 95% CI: 0.05-0.42), respectively. Furthermore, the Combined studies had reduced the risk of SARS-COV 2 infection in the individuals vaccinated with a second dose by about 90% (HR = 0.10, 95% CI: 0.03-0.34). The results of the sub group analysis in the second dose showed well that there was no difference between the effectiveness rates of different types of vaccines ($p - value_{subgroup} = 0.2$) (Figure 8).

Figure 8- Effectiveness of vaccines against COVID-19 infection using Hazard ratio in full vaccinated individuals

Effectiveness of vaccines against COVID-19-related mortality using Hazard ratio in partial-vaccinated individuals

The COVID-19-associated mortality Hazard ratio in the first-dose vaccinated individuals presented in Figure 13 showed well that the first-dose vaccination with BNT162b2 mRNA, ChAdOx1, and Combined studies had reduced the COVID-19-related mortality rate by about 68% (HR = 0.32, 95% CI: 0.23-0.45). However, the people vaccinated with the first dose of BNT162b2 and ChAdOx1 showed 58% (HR = 0.42, 95% CI: 0.30-0.59) and 61% (HR = 0.39, 95% CI: 0.23-0.68) reduction in the mortality Hazard ratio. Besides, the combined studies had reduced the risk of COVID-19-related mortality by about 91% (HR = 0.09, 95% CI: 0.01-0.64). The results of the sub group analysis in the first dose showed well that there was no difference between the effectiveness of different types of vaccines against COVID-19-related mortality rates ($p - value_{subgroup} = 0.31$) (Figure 9).

Figure 9 - Effectiveness of vaccines against COVID-19-related mortality using Hazard ratio in partial-vaccinated individuals

Effectiveness of vaccines against COVID-19-related mortality using Hazard ratio in full-vaccinated individuals

In the individuals fully vaccinated with BNT162b2 mRNA as well as combined studies, the COVID-19-associated mortality Hazard ratio was reduced by approximately 89% (HR = 0.11, 95% CI: 0.03-0.43). However, BNT162b2 mRNA vaccine and the Combined studies

had reduced the risk by about 85% (HR = 0.15, 95% CI: 0.02-0.90) and 96% (HR = 0.04, 95% CI: 0.02-0.08), respectively. The results of the sub group analysis in the second dose showed that there was no difference between the effectiveness of different vaccines against COVID-19-related death ($p - value_{subgroup} = 0.19$) (Figure 10).

Figure 10 - Effectiveness of vaccines against COVID-19-related death using Hazard ratio in full-vaccinated individuals

Effectiveness of vaccines against COVID-19-related death using IRR of Partial- and Full-vaccinated individuals

The results of examining the effectiveness of the first dose of vaccines against COVID-19-related mortality showed that the mortality rate in the people vaccinated with the first dose of BNT162b2 mRNA, mRNA-1273, ChAdOx1, and Combined studies had reduced by about 25% (IRR = 0.75, 95% CI: 0.19-2.93) (Figure 11).

In addition, the effectiveness of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines as well as the Combined studies against COVID-19-related mortality in the second dose was about 82% (IRR = 0.18, 95% CI: 0.15-0.34) (Figure 12).

Figure 11 - Overall effectiveness of vaccines against COVID-19-related mortality in first-dose vaccinated subjects

Figure 12 - Overall effectiveness of vaccines against COVID-19-related mortality in second-dose vaccinated subjects

Discussion

This meta-analysis, which aimed to evaluate the effectiveness of vaccination on the incidence of SARS-COV 2 infection as well as the post-vaccination mortality and hospitalization, was in line with the results of Phase 3 of the Clinical trials on the effectiveness of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 vaccines (10, 21, 22). In other words, the effectiveness of the first and second doses of BNT162b2 mRNA vaccine against SARS-COV 2 infection was 82% and 95%, respectively (10), and in the present study, the effectiveness against SARS-COV 2 infection based on the Pooled estimate was 72% and 89%, respectively. The effectiveness of ChAdOx1 and mRNA-1273 vaccines against the incidence of infection was estimated at 51% and 69% in the first dose and 84% and 80% in the second dose, respectively, which is consistent with the previous studies (21-23).

The increased effectiveness of vaccination against SARS-COV 2 infection after the second dose was clearly observed in this study consistent with the results of other studies. In other words, the increased effectiveness of all vaccines against SARS-COV2 infection was generally about 16% (71% effectiveness in the first dose and 87% in the second). The increased effectiveness of BNT162b2 mRNA vaccine in the second dose compared to the first one was about 15%, and that of mRNA-1273 and ChAdOx1 vaccines was 11% and 33%, respectively. The difference between the effectiveness of two doses of vaccines against the incidence of SARS-COV2 infection in the studies that examined the vaccines heterogeneously (a combination of COVID-19 vaccines on the general population) was about 11% as well. Although the present study aimed to evaluate the effectiveness of homologous vaccines, there were some studies that examined a combination of populations vaccinated with BNT162b2 mRNA, mRNA-1273, and ChAdOx1, and even Ad26.COV2.S in very rare cases, the results of which showed significant effectiveness of the vaccines. That is to say, the effectiveness of these vaccines in reducing the incidence of infection, hospitalization, and mortality associated with COVID-19 in the vaccinated individuals was much higher than other vaccines in some doses. In a heterologous study of the vaccines, Nordstrom et al. (24) showed that their effectiveness varied 67% to 79% depending on their types. The results of the combined studies on the populations vaccinated with different types of vaccines were also consistent with the study by Nordstrom et al, and strengthened the hypothesis of the effect of heterologous vaccines against SARS-COV 2 infection.

On the other hand, the effectiveness of the vaccines increased significantly with the increased post-vaccination follow-up periods, especially after the second dose, so that Hunter et al. (25) reported high effectiveness of the first dose of BNT162b2 mRNA twenty-one days after injection. In the present study, $7 \leq$ days after the first dose and ≥ 5 days after the second dose were considered as partial and full vaccinated, respectively. The results indicated the high effectiveness of the second dose of COVID-19 vaccines (which varied between 20 and 30 days after the first dose) against COVID-19 infection, hospitalization, and mortality.

Although the effectiveness of COVID-19 vaccines against alpha and delta variants has been reported to be lower and milder, the effectiveness of full vaccination against these variants has been shown to be high in other studies (26). In a similar study, Haas et al. (17) reported high effectiveness of two doses of BNT162b2 mRNA vaccine against SARS-COV2 infection, hospitalization, and mortality in B.1.1.7 variant. In addition, some studies on the effects of COVID-19 vaccines on Delta variant did not observe a significant effect 28 days after the first dose (27). This study, which examined the effectiveness of COVID-19 vaccines regardless of SARS-COV2 variants, also showed the effect of complete vaccination on reducing the incidence of infection, hospitalization and mortality.

The effectiveness of complete COVID-19 vaccination in reducing the rate of hospitalization in this study was well demonstrated, consistent with the results of other studies on prevention of COVID-19-related hospitalization (17, 19, 28). The effectiveness against COVID-19-associated hospitalization and mortality was significantly increased with the second dose according to the immunological responses of the subjects, such that the biggest difference in the effectiveness of the two vaccine doses against hospitalization was related to BNT162b2 mRNA and mRNA-1273 with 35% and 29% increase in the second doses, respectively. Reduced mortality rates was another aspect of the effectiveness of COVID-19 vaccines, i.e. the second dose injection was associated with a further 21% decrease in the risk of COVID-19 mortality compared to the first dose (68% in the first dose vs. 89% in the second).

Despite the important results found out on the effectiveness of COVID-19 vaccines against the incidence of infection, hospitalization, and mortality after vaccination, the present study had a number of limitations, including the possibility of vaccination of specific age or occupational groups (health care worker) associated with an increase or decrease in the chance of contracting SARS-COV2 infection. However, the confounding effect of the background variables was somewhat controlled through the use of HR adjusted studies. Herd immunity was another issue that could distort the overall results; i.e. with increasing follow-ups, the risk of infection in the community and non-vaccinated people would gradually decrease, and this would overestimate the effectiveness of various COVID-19 vaccines.

Conclusion:

The results of this study showed that vaccination with BNT162b2 mRNA, mRNA-1273, and ChAdOx1, and even their combination in different populations was associated with increased effectiveness against SARS-COV2 infection, hospitalization, and mortality in the first and second doses. On the other hand, due to the higher effectiveness of the second dose compared to the first one in reducing the incidence of infection, mortality, and hospitalization associated with COVID-19, injection of the second and the booster doses seems necessary for high risk individuals. Furthermore, considering the increasing trend of vaccine effectiveness, the use of other preventive methods such as social distancing and wearing facemasks, preferably 0-7 days after the first dose, seems necessary.

Conflict of interest:

None declared.

References:

- .1 Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. *Nature*. 2004;430(6996):242-9.
- .2 Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. *EClinicalMedicine*. 2020;21:100331.
- .3 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The lancet*. 2020;395(10223):49.506-7
- .4 Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The lancet*. 2020;395(10223):507-13.
- .5 Organization WH. WHO coronavirus disease (COVID-19) dashboard. 2020. 2020.
- .6 Sharma O, Sultan AA, Ding H, Triggler CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. *Frontiers in immunology*. 2020;11:2413.
- .7 Forni G, Mantovani A. COVID-19 vaccines :where we stand and challenges ahead. *Cell Death & Differentiation*. 2021;28(2):626-39.
- .8 Verbeke R, Lentacker I, De Smedt SC, Dewitte H. The dawn of mRNA vaccines: The COVID-19 case. *Journal of Controlled Release*. 2021;333:511-20.
- .9 Angel Y, Spitzer A ,Henig O, Saiag E, Sprecher E, Padova H, et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. *JAMA*. 2021.
- .10 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England Journal of Medicine*. 2020.
- .11 MJ EO, Juanes de Toledo B. Pfizer-BioNTech, la primera vacuna ARNm contra la COVID-19, parece segura y eficaz.
- .12 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet*. 2021;397.111-99:(10269)
- .13 Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. *New England Journal of Medicine*. 2021;384(23):2187-201.
- .14 Helfand BK, Webb M, Gartaganis SL, Fuller L, Kwon C-S, Inouye SK. The exclusion of older persons from vaccine and treatment trials for coronavirus disease 2019—missing the target. *JAMA internal medicine*. 2020;180(11):1546-9.
- .15 Welch MJ, Lally R, Miller JE, Pittman S, Brodsky L ,Caplan AL, et al. The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials. *Clinical trials*. 2015;12(5):503-10.
- .16 Cooper DM, Afghani B, Byington CL, Cunningham CK, Golub S, Lu KD, et al. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges. *Pediatric research*. 2021:1-5.
- .17 Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *The Lancet*. 2021;397(10287):1819-29.
- .18 Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study. 2021.
- .19 Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. *New England Journal of Medicine*. 2021;385(15):1355-71.
- .20 Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. *The Journal of infectious diseases*. 2010;201(11):1607-10.

- .21 Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. *New England Journal of Medicine*. 2021.
- .22 Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *New England Journal of Medicine*. 2021;384(5):403-16.
- .23 Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. *New England Journal of Medicine*. 2021;384(15):1412-23.
- .24 Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. *The Lancet Regional Health-Europe*. 2021:100249.
- .25 Hunter PR, Brainard JS. Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of 'real-world' vaccination outcomes from Israel. *Medrxiv*. 2021.
- .26 Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. *N Engl J Med*. 2021:585-94.
- .27 Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet*. 2021.
- .28 Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *bmj*. 2021;373.
- .29 Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England, multicentre prospective cohort study (the SIREN Study). 2021.
- .30 Fabiani M, Ramigni M, Gobetto V, Mateo-Urdiales A, Pezzotti P, Piovesan C. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. *Eurosurveillance*. 2021;26.2100420:(17)
- .31 Thompson MG, Burgess JL, Naleway A, Tyner H, Yoon SK, Meece J, et al. Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines. *medRxiv*. 2021.
- .32 Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. *The Lancet Infectious Diseases*. 2021.
- .33 Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan A, Niesen MJ, et al. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. *MedRxiv*. 2021.
- .34 Regev-Yochay G, Amit S, Bergwerk M, Lipsitch M, Leshem E, Kahn R, et al. Decreased infectivity following BNT162b2 vaccination: a prospective cohort study in Israel. *The Lancet Regional Health-Europe*. 2021;7:100150.
- .35 Puranik A, Lenehan PJ, Silvert E, Niesen MJ, Corchado-Garcia J, O'Horo JC, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. *MedRxiv*. 2021.
- .36 Katz MA, Harlev EB, Chazan B, Chowers M, Greenberg D, Peretz A, et al. Covid-19 Vaccine Effectiveness in Healthcare Personnel in six Israeli Hospitals (CoVEHPI). *medRxiv*. 2021.
- .37 Cabezas C, Coma E, Mora-Fernandez N, Li X, Martinez-Marcos M, Fina F, et al. Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study. *bmj*. 2021;374.
- .38 Glatman-Freedman A, Bromberg M, Dichtiar R, Hershkovitz Y, Keinan-Boker L. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases :A nation-wide retrospective longitudinal multiple cohort analysis using individualised data. *EBioMedicine*. 2021;72:103574.

- .39 Zacay G, Shasha D, Bareket R, Kadim I, Hershkowitz Sikron F, Tsamir J, et al., editors. BNT162b2 vaccine effectiveness in preventing asymptomatic infection with SARS-CoV-2 virus: a nationwide historical cohort study. *Open Forum Infectious Diseases*; 2021.
- .40 Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. *The Lancet*. 2021;397(10286):1725-35.
- .41 Emborg H-D, Valentiner-Branth P, Schelde AB, Nielsen KF, Gram MA, Moustsen-Helms IR, et al. Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk groups. *medRxiv*. 2021.
- .42 Bjork J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F. Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age population—first results from a cohort study in Southern Sweden. *medRxiv*. 2021.
- .43 Monge S, Olmedo C, Alejos B, Lapeña MF, Sierra MJ, Limia A. Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain. *Emerging infectious diseases*. 2021;27(10):2595.
- .44 Ghosh S, Shankar S, Chatterjee K, Chatterjee K, Yadav AK, Pandya K, et al. COVISHIELD (AZD1222) vaccine effectiveness among healthcare and frontline Workers of INdian Armed Forces: Interim results of VIN-WIN cohort study. *medical journal armed forces india*. 2021;77:S264-S70.
- .45 Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight US locations, December 2020–March 2021. *Morbidity and Mortality Weekly Report*. 2021;70(13):495.
- .46 Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617. (Delta) variant predominance—eight US locations, December 2020–August 2021. *Morbidity and Mortality Weekly Report*. 2021;70(34):1167.
- .47 Bouton TC, Lodi S, Turcinovic J, Schaeffer B, Weber SE, Quinn E, et al., editors. COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination strain sequences among healthcare workers at an urban academic medical center: a prospective cohort study. *Open Forum Infectious Diseases*; 2021.
- .48 Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. *Eurosurveillance*. 2021;26(21):2100438.
- .49 Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA, et al. Effectiveness of mRNA Covid-19 Vaccine among US Health Care Personnel. *New England Journal of Medicine*. 2021.
- .50 Ye P, Fry L, Liu H, Ledesma S, Champion JD. COVID outbreak after the 1st dose of COVID vaccine among the nursing home residents: What happened? *Geriatric Nursing*. 2021;42(5):1105-8.
- .51 Pilishvili T, Fleming-Dutra KE, Farrar JL, Gierke R, Mohr NM, Talan DA, et al. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel—33 US Sites, January–March 2021. *Morbidity and Mortality Weekly Report*. 2021;70(20):753.
- .52 Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, Guevara M, Fernández-Huerta M, Burgui C, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. *Eurosurveillance*. 2021;26(39):2100894.
- .53 Carazo S, Talbot D, Boulianne N, Brisson M, Gilca R, Deceuninck G, et al. Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada. *medRxiv*. 2021.
- .54 Azamgarhi T, Hodgkinson M, Shah A, Skinner JA, Hauptmannova I, Briggs TW, et al. BNT162b2 vaccine uptake and effectiveness in UK healthcare workers—a single centre cohort study. *Nature Communications*. 2021;12(1):1-6.
- .55 Bobdey S, Kaushik S, Sahu R, Naithani N, Vaidya R, Sharma M, et al. Effectiveness of ChAdOx1 nCoV-19 Vaccine: Experience of a tertiary care institute. *medical journal armed forces india*. 2021;77:S271-S7.

- .56 Issac A, Kochuparambil JJ, Elizabeth L. SARS-CoV-2 Breakthrough Infections among the Healthcare Workers Post-Vaccination with ChAdOx1 nCoV-19 Vaccine in the South Indian State of Kerala. medRxiv. 2021.
- .57 Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D, Lutterloh E, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status—New York, May 3–July 25, 2021. Morbidity and Mortality Weekly Report. 2021;70(37):1306.
- .58 Flacco ME, Soldato G, Acuti Martellucci C, Carota R, Di Luzio R, Caponetti A, et al. Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province. Vaccines. 2021;9(6):628.
- .59 Tande AJ, Pollock BD, Shah ND, Farrugia G, Virk A, Swift M, et al. Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular Screening. Clinical Infectious Diseases. 2021.
- .60 Shah AS, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households. MedRxiv. 2021.
- .61 Andrejko KL, Pry J, Myers JF, Jewell NP, Openshaw J, Watt J, et al. Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California. Clinical Infectious Diseases. 2021.
- .62 Fillmore N, La J, Zheng C, Doron S, Do N, Monach P, et al. The COVID-19 Hospitalization Metric in the Pre-and Post-vaccination Eras as a Measure of Pandemic Severity: A Retrospective, Nationwide Cohort Study. 2021.
- .63 Chung H, He S, Nasreen S, Sundaram M, Buchan S, Wilson S, et al. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada. 2021.
- .64 Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021. Morbidity and Mortality Weekly Report. 2021;70(32):1081.
- .65 Nunes B, Rodrigues AP, Kislaya I, Cruz C, Peralta-Santos A, Lima J, et al. mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021. Eurosurveillance. 2021;26(38):2100833.
- .66 Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. Morbidity and Mortality Weekly Report. 2021;70(38):1337.
- .67 Griffin JB, Haddix M, Danza P, Fisher R, Koo TH, Traub E, et al. SARS-CoV-2 infections and hospitalizations among persons aged ≥ 16 years, by vaccination status—Los Angeles County, California, May 1–July 25, 2021. Morbidity and Mortality Weekly Report. 2021;70(34):1170.
- .68 Britton A, Slifka KMJ, Edens C, Nanduri SA, Bart SM, Shang N, et al. Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks—Connecticut, December 2020–February 2021. Morbidity and Mortality Weekly Report. 2021;70(11):021.
- .69 Butt AA, Nafady-Hego H, Chemaitelly H, Abou-Samra A-B, Al Khal A, Coyle PV, et al. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. International Journal of Infectious Diseases. 2021;110:353-8.
- .70 Baltas I, Boshier FA, Williams CA, Bayzid N, Cotic M, Guerra-Assunção JA, et al. Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals. Clinical Infectious Diseases. 2021.
- .71 Bernal JL, Andrews N, Gower C, Stowe J, Tessier E, Simmons R, et al. Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19. medRxiv. 2021.
- .72 Glampson B, Brittain J, Kaura A, Mulla A, Mercuri L, Brett SJ, et al. Assessing COVID-19 Vaccine Uptake and Effectiveness Through the North West London Vaccination Program: Retrospective Cohort Study. JMIR public health and surveillance. 2021;7(9):e30010.

- .73 Moustsen-Helms IR, Emborg H-D, Nielsen J, Nielsen KF, Krause TG, Molbak K, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers—a Danish cohort study. MedRxiv. 2021.
- .74 Waldman SE, Adams JY, Albertson TE, Juárez MM, Myers SL, Atreja A, et al. Real-world impact of vaccination on coronavirus disease 2019 (COVID-19) incidence in healthcare personnel at an academic medical center. Infection Control & Hospital Epidemiology. 2021:1-7.

medRxiv preprint doi: <https://doi.org/10.1101/2021.11.03.21265349>; this version posted November 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 1: Incidence rate of SARS-COV 2 infection after the first and second doses in people with a history of COVID-19 vaccination

First Author	Country	type of vaccines	type of study	Group of study	SARS-COV 2 Incidence									
					Partial vaccinated		Unvaccinated		Rate Ratio*	Full Vaccinated		Unvaccinated		Rate Ratio*
					Cases	Pearson day	Cases	Pearson day		Cases	Pearson day	Cases	Pearson day	
Noa Dagan (23)	Israel	BNT162b2 mRNA	prospective cohort study	age of ≥ 16 and older	3533	262180	3971	26162	0.888	-	-	-	-	-
Hall V FFPH (29)	UK	BNT162b2 mRNA	prospective cohort study	Healthcare workers.	71	87278	977	710587	0.592	9	20978	977	710587	0.312
Massimo Fabiani (30)	Italy	BNT162b2 mRNA	retrospective cohort	Healthcare workers.	60	73914	128	62330	0.395	0	35596	11	14186	0.000
Eric J Haas (17)	Israel	BNT162b2 mRNA	prospective cohort study	Age of 16 and older.	-	-	-	-	-	6266	201882183	109876	120076136	0.034
M.G. Thompson (31)	USA	BNT162b2 mRNA	prospective cohort study	health care workers	8	49516	156	127971	0.133	3	120653	156	127971	0.020
Sara Y Tartof (18)	USA	BNT162b2 mRNA	retrospective cohort	Health care workers.	585	12986040	160280	449593130	0.126	3414	109442695	160280	449593130	0.088
Madhumita Shrotri (32)	UK	BNT162b2 mRNA	prospective cohort study	aged 65 years and older	50	17690	723	338003	1.321	-	-	-	-	-
Yoel Angel (9)	Israel	BNT162b2 mRNA	retrospective cohort	healthcare workers	68	117389	45	15069	0.194	27	168571	55	25359	0.074
Colin Pawlowski (33)	USA	BNT162b2 mRNA	retrospective cohort	Aged ≥ 18 years.	401	2942986	1232	285102	0.315	82	1914500	563	1828464	0.139
Gili Regev-Yochay (34)	Israel	BNT162b2 mRNA	prospective cohort study	healthcare workers	30	54832	115	199126	0.947	19	329071	115	199126	0.100
Arjun Puranik (35)	USA	BNT162b2 mRNA	retrospective cohort	aged ≥ 18 years	58	180675	69	180675	0.840	72	2332005	321	2526895	0.243
Mark A. Katz (36)	Israel	BNT162b2 mRNA	prospective cohort study	healthcare workers	-	-	-	-	-	4	68574	9	10027	0.065
Carmen Cabezas (37)	Catalonia	BNT162b2 mRNA	prospective cohort study	healthcare workers	358	5528745	1961	2269003	0.075	222	4877162	961	2269003	0.107
Aharona Freedman (38)	Israel	BNT162b2 mRNA	retrospective cohort	Aged ≥ 16 years	7166	14289253	133994	1197012	0.448	1639	14060250	95655	89535711	0.109
Galia Zacay (39)	Israel	BNT162b2 mRNA	retrospective cohort	aged ≥ 16 years	59	28727	382	71797	0.386	15	26260	382	71797	0.107
Victoria Jane Hall (40)	UK	BNT162b2 mRNA	prospective cohort study	healthcare workers	71	87278	977	710587	0.592	9	20978	977	710587	0.312
Hanne-Dorthe Emborg (41)	Denmark	BNT162b2 mRNA	prospective cohort study	prioritized risk groups,	610	4415441	13297	55131206	0.573	304	13612638	13297	55131206	0.093
Jonas Björk (42)	Sweden	BNT162b2 mRNA	prospective cohort study	aged 18-64 years,	25	102830	4155	9902620	0.579	8	133616	4155	9902620	0.143
Susana Monge (43)	Spain	BNT162b2 mRNA	prospective cohort study	aged ≥ 65 years	2690	218621	22	218621	1.190	885	207774	20	1997	0.425
Madhumita Shrotri (32)	UK	ChAdOx1	prospective cohort study	aged ≥ 65 years	82	32672	723	338003	1.173	-	-	-	-	-
Subhadeep Ghosh (44)	India	ChAdOx1	prospective cohort study	healthcare workers	1159	49653918	10061	106594492	0.247	2512	58674639	10061	106594492	0.454
M.G. Thompson (31)	USA	mRNA-1273	prospective cohort study	health care workers	3	31231	156	127971	0.079	2	40394	156	127971	0.041
Colin Pawlowski (33)	USA	mRNA-1273	retrospective cohort	Aged ≥ 18 years.	97	946890	303	92771	0.314	7	495550	101	478322	0.067
Arjun Puranik (35)	USA	mRNA-1273	retrospective cohort	aged ≥ 18 years	74	180810	69	180675	1.071	38	2214873	321	2526895	0.135
Mark G. Thompson (45)	USA	Combination†	prospective cohort study	healthcare workers	8	41856	161	116657	0.138	3	78902	161	116657	0.028
Ashley Fowlkes (46)	USA	Combination†	prospective cohort study	healthcare workers	-	-	-	-	-	34	454832	194	181357	0.070
Tara C. Bouton (47)	USA	Combination†	prospective cohort study	healthcare workers,	29	251790	329	40630	0.142	-	-	-	-	-

* Rate Ratio computed

† BNT162b2 mRNA and mRNA-1273 and ChAdOx1

Table 2 - Positive tests for SARS-COV 2 infection after the first and second doses in people with a history of COVID-19 vaccination

First Author	Country	type of vaccines	type of study	Group of study	Positive SARS-COV 2 Infection									
					Partial vaccinated		Unvaccinated		Odds Ratio*	Full Vaccinated		Unvaccinated		Odds Ratio*
					Cases	Total	Cases	Total		Cases	Total	Cases	Total	
Hall V FFPH (29)	UK	BNT162b2 mRNA	prospective cohort study	Healthcare workers.	71	20641	977	2683	0.006	9	1607	977	2683	0.009
Iván Martínez-Baz (48)	Spain	BNT162b2 mRNA	prospective cohort study	aged ≥ 18 years	90	310	6980	19580	0.738	61	491	6980	19580	0.256
T. Pilishvili (49)	USA	BNT162b2 mRNA	case–control study	healthcare workers	122	1472	707	3420	0.347	149	1472	882	3420	0.324
Ping Ye, DNP (50)	USA	BNT162b2 mRNA	retrospective cohort	nursing home residents	68	86	5	5	0.000	5	17	5	5	0.000
Tamara Pilishvili (51)	USA	BNT162b2 mRNA	case–control study	health care workers	214	926	340	642	0.267	-	-	-	-	-
Iván Martínez-Baz (52)	Spain	BNT162b2 mRNA	prospective cohort study	aged ≥ 18 year	351	2022	4811	14348	0.416	1070	7972	4811	14348	0.307
Sara Carazo (53)	Canada	BNT162b2 mRNA	case–control study	healthcare workers	2130	26719	6323	24986	0.256	68	2022	6323	24986	0.103
Carmen Cabezas (37)	Catalonia	BNT162b2 mRNA	prospective cohort study	healthcare workers	1607	102161	4440	11061	0.403	-	-	-	-	-
Galia Zacay (39)	Israel	BNT162b2 mRNA	retrospective cohort	aged ≥16 years	59	1445	382	6286	0.658	16	2941	382	6286	0.085
Tariq Azamgarhi (54)	UK	BNT162b2 mRNA	prospective cohort study	healthcare workers	23	1408	26	890	0.510	-	-	-	-	-
Jamie Lopez Bernal (28)	UK	BNT162b2 mRNA	case–control study	age ≥70 years,	448	1956	15287	36806	0.416	-	-	-	-	-
Jamie Lopez Bernal (26)	UK	BNT162b2 mRNA	case–control study	aged ≥16 years,	43	2884	4043	96371	0.346	122	15749	4043	96371	0.178
T. Pilishvili (49)	USA	mRNA-1273	case–control study	health care workers	18	1472	156	3420	0.259	18	1472	190	3420	0.210
Tamara Pilishvili (51)	USA	mRNA-1273	case–control study	health care workers	68	268	340	642	0.302	-	-	-	-	-
Iván Martínez-Baz (52)	Spain	mRNA-1273	prospective cohort	aged ≥ 18 year	70	517	4811	14348	0.310	85	1127	4811	14348	0.162
Sara Carazo (53)	Canada	mRNA-1273	case–control study	healthcare workers	110	1639	6323	24986	0.212	2	128	6323	24986	0.047
Jamie Lopez Bernal (26)	UK	mRNA-1273	case control	aged ≥16 years,	592	25913	4043	96371	0.534	218	8244	4043	96371	0.620
Saurabh Bobdey (55)	India	ChAdOx1	prospective cohort study	-	27	239	19	91	0.503	67	2863	19	94	0.095
Iván Martínez-Baz (48)	Spain	ChAdOx1	prospective cohort study	aged ≥ 18 years	99	524	6980	19580	0.420	-	-	-	-	-
Iván Martínez-Baz (52)	Spain	ChAdOx1	prospective cohort study	aged ≥ 18 year -	302	1599	4811	14348	0.462	272	1539	4811	14348	0.426
Aleena Issac (56)	India	ChAdOx1	prospective cohort study	Healthcare Workers	-	-	-	-	-	16	243	35	80	0.091
Jamie Lopez Bernal (28)	UK	ChAdOx1	case–control study	adult age ≥70 years,	396	1342	15287	36806	0.585	-	-	-	-	-
Eli S. Rosenberg (57)	USA	Combination†	prospective cohort	adults aged ≥18	-	-	-	-	-	9675	10135322	38505	3742197	0.092
Maria Elena Flacco (58)	Italy	Combination†	retrospective cohort	Aged ≥ 18 years.	12	69539	6948	17566	0.004	-	-	-	-	-
Aaron J. Tande (59)	USA	Combination†	retrospective cohort	aged ≥18 years	42	3006	1436	4533	0.433	-	-	-	-	-
Anoop S V Shah (60)	Scotland	Combination†	prospective cohort study	healthcare workers	1152	109074	3191	14451	0.473	-	-	-	-	-
Kristin L. Andrejko (61)	USA	Combination†	case–control study	aged ≥18 years	51	150	454	767	0.355	20	106	454	767	0.160
Nathanael Fillmore (62)	USA	Combination†	retrospective cohort	-	-	-	-	-	-	1546	3627	6326	11569	0.616
Tara C. Bouton (47)	USA	Combination†	prospective cohort study	healthcare workers	96	7109	329	3481	0.131	17	5913	329	3481	0.028
Hannah Chung (63)	Canada	Combination†	case–control study	aged ≥16 years	2050	21272	51220	302761	0.524	73	21272	51220	302761	0.017
Alyson Cavanaugh (64)	USA	Combination†	case–control study	aged ≥18 years	17	56	179	463	0.692	50	219	179	463	0.469

* Odds Ratio computed

† BNT162b2 mRNA and mRNA-1273 and ChAdOx1

Table 3 – Covid-19-related mortality after the first and second doses in people vaccinated with BNT162b2 mRNA

First Author	Vaccine type	Country	type of study	Group of study	SARS-COV 2 Mortality									
					Partial vaccinated		Unvaccinated		Rate Ratio*	Full Vaccinated		Unvaccinated		Rate Ratio*
					death	Pearson day	death	Pearson day		death	Pearson day	death	Pearson day	
Noa Dagan (23)	BNT162b2 mRNA	Israel	prospective cohort study	age of ≥ 16 and older	2	264538	6	26447	0.333	9	4322	32	4316	0.281
Eric J Haas (17)	BNT162b2 mRNA	Israel	prospective cohort study	Age of 16 and older.	-	-	-	-	-	138	201882183	715	120076136	0.115
Arjun Puranik (35)	BNT162b2 mRNA	USA	retrospective cohort	aged ≥18 years	0	180814	0	180814	-	0	2333860	4	2537030	0.000
Carmen Cabezas (37)	BNT162b2 mRNA	Catalonia	prospective cohort study	healthcare workers	153	3030779	272	639188	0.119	33	2745713	272	639181	0.028
Aharona Freedman (38)	BNT162b2 mRNA	Israel	retrospective cohort	Aged ≥16 years	178	14289253	819	119701	1.821	61	14060250	567	89535711	0.685
Hanne-Dorthe Emborg (41)	BNT162b2 mRNA	Denmark	prospective cohort study	-	203	4551842	445	55910554	5.603	25	13735570	445	55910554	0.229
Arjun Puranik (35)	mRNA-1273	USA	retrospective cohort	aged ≥18 years	0	180951	0	180951	-	0	2215773	4	2537030	0.000
Subhadeep Ghosh (44)	ChAdOx1	India	prospective cohort study	healthcare workers	16	49653918	37	106594492	0.928	7	58674639	37	106594492	0.344
Baltazar Nunes (65)	Combination†	Portugal	prospective cohort study	aged ≥65 years	11	21560915	90	52945805	0.300	14	48853060	90	52945805	0.169

* Rate Ratio computed

† BNT162b2 mRNA and mRNA-1273 and ChAdOx1

medRxiv preprint doi: <https://doi.org/10.1101/2021.11.03.21262319>; this version posted November 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

medRxiv preprint doi: <https://doi.org/10.1101/2021.11.05.21265819>; this version posted November 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 4: COVID-19-related hospitalization rate after the first and second doses of vaccinated patients

First Author	Vaccine type	Country	type of study	Group of study	SARS-COV 2 Hospitalization									
					Partial vaccinated		Unvaccinated		Odds Ratio*	Full Vaccinated		Unvaccinated		Odds Ratio*
					Cases	Total	Cases	Total		Cases	Total	Cases	Total	
Iván Martínez-Baz (52)	BNT162b2 mRNA	Spain	prospective cohort study	aged ≥ 18 year	6	2022	214	14348	0.197	20	7972	214	14348	0.166
Wesley H. Self (66)	BNT162b2 mRNA	USA	case–control study	Among Adults	-	-	-	-	-	128	738	1463	2362	0.129
Jamie Lopez Bernal (28)	BNT162b2 mRNA	UK	case–control study	age ≥70 years,	128	1400	1365	8892	0.555	-	-	-	-	-
M.G. Thompson (19)	BNT162b2 mRNA	USA	case–control study	aged ≥50 years	140	1444	3695	20406	0.486	220	9848	3695	20406	0.103
Iván Martínez-Baz (52)	mRNA-1273	Spain	prospective cohort study	Aged ≥ 18 year	2	517	214	14348	0.256	1	1127	214	14348	0.059
M.G. Thompson (19)	mRNA-1273	USA	case–control study	aged ≥50 years	91	1639	3695	20406	0.266	145	7508	3695	20406	0.089
Iván Martínez-Baz (52)	ChAdOx1	Spain	prospective cohort study	aged ≥ 18 year	8	1599	214	14348	0.332	2	1539	214	14348	0.086
Jamie Lopez Bernal (28)	ChAdOx1	UK	case–control study	adult age ≥70	9	126	1365	8892	0.424	-	-	-	-	-
Anoop S V Shah (60)	Combination†	Scotland	prospective cohort study	healthcare workers	19	111081	158	144529	0.156	-	-	-	-	-
Jennifer B. Griffin (67)	Combination†	USA	prospective cohort study	aged ≥16 years	29	1431	1289	30801	0.474	136	10895	1289	30801	0.289

* Odds Ratio computed

† BNT162b2 mRNA and mRNA-1273 and ChAdOx1

Table 5 - Risk ratio of SARS-COV 2 infection and COVID-19-related mortality in patients with a history of first- and second-dose vaccination

First Author	Vaccine type	Country	type of study	Group of study	HR SARS-COV 2 infection						HR death related to the COVID-19					
					Partial vaccinated			Full Vaccinated			Partial vaccinated			Full Vaccinated		
					HR*	95% CI		HR*	95% CI		HR*	95% CI		HR*	95% CI	
Hall V FFPH (29)	BNT162b2 mRNA	UK	prospective cohort study	Healthcare workers.	0.3	0.15	0.45	0.15	0.04	0.26	-	-	-	-	-	-
Amadea Britton (68)	BNT162b2 mRNA	USA	retrospective cohort	-	0.37	0.21	0.67	-	-	-	-	-	-	-	-	-
Adeel A. Butt (69)	BNT162b2 mRNA	Qatar	prospective cohort study	-	-	-	-	-	-	-	-	-	-	0.35	0.22	0.55

Ioannis Baltas (70)	BNT162b2 mRNA	UK	case–control study	-	-	-	-	-	-	-	0.34	0.178	0.651	-	-	-
M.G. Thompson (31)	BNT162b2 mRNA	USA	prospective cohort study	healthcare workers	0.2	0.1	0.4	0.07	0.02	0.22	-	-	-	-	-	-
Sara Y Tartof (18)	BNT162b2 mRNA	USA	retrospective cohort	Aged ≥12 years.	0.42	0.39	0.46	0.27	0.26	0.28	-	-	-	-	-	-
Madhumita Shrotri (32)	BNT162b2 mRNA	UK	prospective cohort study	age of ≥ 65	0.77	0.37	1.58	-	-	-	-	-	-	-	-	-
Mark A. Katz (36)	BNT162b2 mRNA	Israel	prospective cohort study	healthcare workers	-	-	-	0.55	0.018	0.174	-	-	-	-	-	-
Jamie Lopez Bernal (71)	BNT162b2 mRNA	UK	retrospective cohort	aged ≥70 years	-	-	-	-	-	-	0.56	0.47	0.68	0.31	0.14	0.69
Ben Glampson (72)	BNT162b2 mRNA	UK	retrospective cohort	Aged ≥16 years.	0.42	0.36	0.5	-	-	-	-	-	-	-	-	-
Carmen Cabezas (37)	BNT162b2 mRNA	Catalonia	prospective cohort study	healthcare workers	0.13	0.11	0.14	0.13	0.11	0.16	0.31	0.26	0.39	0.03	0.02	0.04
Tariq Azamgarhi (54)	BNT162b2 mRNA	UK	prospective cohort study	healthcare workers	0.3	0.09	0.94	-	-	-	-	-	-	-	-	-
Jamie Lopez Bernal (28)	BNT162b2 mRNA	UK	case–control study	adult age ≥70 years,	-	-	-	-	-	-	0.49	0.38	0.63	-	-	-
Ida Rask Moustsen-Helms (73)	BNT162b2 mRNA	Denmark	retrospective cohort	healthcare workers,	0.17	0.04	0.28	0.29	0.82	0.95	-	-	-	-	-	-
Peter Nordstrom (24)	BNT162b2 mRNA	Sweden	Prospective cohort	-	-	-	-	0.22	0.21	0.22	-	-	-	-	-	-
M.G. Thompson (31)	mRNA-1273	USA	prospective cohort study	health care workers	0.17	0.05	0.6	0.18	0.04	0.8	-	-	-	-	-	-
Peter Nordstrom (24)	mRNA-1273	Sweden	Prospective cohort	-	-	-	-	0.13	0.12	0.16	-	-	-	-	-	-
Saurabh Bobdey (55)	ChAdOx1	India	prospective cohort study	-	0.559	0.327	0.954	0.14	0.0763	0.184	-	-	-	-	-	-
Ioannis Baltas (70)	ChAdOx1	UK	case–control study	-	-	-	-	-	-	-	0.216	0.067	0.696	-	-	-
Madhumita Shrotri (32)	ChAdOx1	UK	prospective cohort study	aged ≥ 65 years	0.95	0.5	1.84	-	-	-	-	-	-	-	-	-
Jamie Lopez Bernal (71)	ChAdOx1	UK	retrospective cohort	aged ≥70 years	-	-	-	-	-	-	0.45	0.34	0.59	-	-	-
Ben Glampson (72)	ChAdOx1	UK	retrospective cohort	Aged ≥16 years.	0.59	0.49	0.71	-	-	-	-	-	-	-	-	-
Peter Nordstrom (24)	ChAdOx1	Sweden	Prospective cohort	-	-	-	-	0.55	0.42	0.59	-	-	-	-	-	-
Mark G. Thompson (45)	Combination†	USA	prospective cohort study	healthcare workers	0.2	0.1	0.41	0.11	0.03	0.32	-	-	-	-	-	-
Ashley Fowlkes (46)	Combination†	USA	prospective cohort study	healthcare workers				0.2	0.12	0.31	-	-	-	-	-	-
Sarah E. Waldman (74)	Combination†	USA	retrospective cohort	age ≥ 18 year old	0.53	0.4	0.71	0.22	0.12	0.42	-	-	-	-	-	-
Maria Elena Flacco (58)	Combination†	Italy	retrospective cohort	Aged ≥ 18 years.	0.05	0.04	0.06	0.02	0.01	0.03	0.03	0.01	0.08	0.02	0	0.12
Baltazar Nunes (65)	Combination†	Portugal	prospective cohort study	Aged ≥ 65 years.	-	-	-	-	-	-	0.23	0.12	0.44	0.04	0.02	0.08

* Hazard Ratio adjusted in each study

† BNT162b2 mRNA and mRNA-1273 and ChAdOx1